secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2025-12-04T23:59:59+00:00
Accession:  0001193125-25-307516
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa completes FDA Type C meeting; gains clarity on accelerated (Z)-endoxifen development
--------------------------------------------------------------------------------

- FDA provided feedback on regulatory pathways for (Z)-endoxifen across metastatic, neoadjuvant, and risk-reduction settings.
- Company submitted IND for metastatic breast cancer program and awaits FDA feedback.
- Phase 2 EVANGELINE trial continuing in neoadjuvant ER+/HER2- breast cancer.
- Nearly 800 participants in completed trials; no MTD identified up to 360 mg/day.
- Additional IND submissions planned in 2026 for combination strategies beyond monotherapy and breast cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312525307516/0001193125-25-307516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312525307516/atos-20251204.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-307516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer